Organization
University of Erlangen-Nuremberg, Erlangen, Germany
4 abstracts
Abstract
AN OPEN-LABEL STUDY TO EVALUATE BIOMARKERS AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) PATIENTS TREATED WITH PAQUINIMOD (ABR-215757) Org: Skåne University Hospital, Lund, Sweden, University of Erlangen-Nuremberg, Erlangen, Germany, Charité Universitätsmedizin Berlin, Berlin, Germany, Active Biotech AB, Lund, Sweden, University Hospital Zurich, Zurich, Switzerland,
Abstract
ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS Org: Universiy of Erlangen-Nuremberg, Erlangen, Orgentec Diagnostica, Mainz, Germany, Instituto de Reumatologia de Sao Paulo, Sao Paulo, Brazil, University of Erlangen-Nuremberg, Erlangen, Germany, Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria,
Abstract
ABATACEPT BUT NOT TNF INHIBITORS BLOCK AUTOANTIBODY-MEDIATED CYTOKINE PRODUCTION BY MONOCYTES Org: University of Erlangen-Nuremberg, Erlangen, Germany, University of Chengdu, Chengdu, China, Universidade de São Paulo, Sao Paulo, Brazil, Orgentec Inc., Mainz, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENT IN FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Toronto Western Research Institute, Toronto, Canada, University Hospital Southampton, Southampton, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, University Paris Diderot, Paris, France, University of New South Wales, Kogarah, Australia,